Table 4.
Standardised incidence ratios and absolute excess risks of subsequent breast cancer among patients with bone sarcoma by calendar year at diagnosis, age at diagnosis, site and follow-up.
| All | Osteosarcoma | Ewing sarcoma | |||||||
|---|---|---|---|---|---|---|---|---|---|
| No. Obs/exp | SIR (95% CI) | AER (95% CI) | No. Obs/exp | SIR (95% CI) | AER (95% CI) | No. Obs/exp | SIR (95% CI) | AER (95% CI) | |
| Calendar Year | |||||||||
| 1958–1979 | 11/4.0 |
2.7 (1.4–4.9) |
21.6 (4.6–48.4) |
8/3.3 |
2.4 (1.1–4.8) |
19.7 (0.7–52.1) |
3/0.7 |
4.2 (0.9–12.3) |
27.0 (−1.1 to 95.2) |
| 1980–1999 | 6/2.4 |
2.5 (0.9–5.5) |
13.2 (−0.6 to 38.8) |
3/1.9 |
1.6 (0.3–4.6) |
5.6 (−6.6 too 35.2) |
3/0.5 |
6.5 (1.3–19.1) |
31.4 (2.0–103) |
| 2000–2015 | 1/0.8 |
1.3 (0.0–7.5) |
2.2 (−6.2 to 41.3) |
1/0.6 |
1.6 (0.0–8.7) |
4.7 (−8.0 to 64.1) |
0/0.1 | - | - |
| Age at diagnosis | |||||||||
| 0–9 years | 1/0.2 |
6.7 (0.2–37.5) |
9.6 (−1.4 to 61.2) |
0/0.1 | - | - | 1/0.1 |
11.9 (0.3–66.3) |
17.4 (−1.1 to 104) |
| 10–19 years | 7/1.8 |
3.9 (1.5–7.9) |
15.2 (2.9–36.9) |
4/1.4 |
2.8 (0.8–7.2) |
10.4 (−1.3 to 35.4) |
3/0.4 |
7.4 (1.5–21.8) |
28.1 (2.3–90.5) |
| ≥20 years | 10/5.1 |
1.9 (0.9–3.6) |
17.0 (−1.2 to 46.2) |
8/4.4 |
1.8 (0.8–3.6) |
16.2 (−4.0 to 50.5) |
2/0.8 |
2.5 (0.3–9.1) |
20.0 (−9.1 to 106) |
| Site | |||||||||
| Extremity | 13/6.2 |
2.1 (1.1–3.6) |
11.4 (1.2–26.8) |
10/5.3 |
1.9 (0.9–3.5) |
10.2 (−1.0 to 28.2) |
3/0.9 |
3.2 (0.7–9.3) |
15.5 (−2.5 to 59.0) |
| Central | 5/0.8 |
6.5 (2.1–15.2) |
40.5 (8.2–104) |
2/0.4 |
4.6 (0.6–16.5) |
48.3 (−6.0 to 210) |
3/0.3 |
9.0 (1.9–26.4) |
36.9 (4.0–117) |
| Pelvic | 1/0.2 |
4.6 (0.1–25.4) |
20.8 (−5.2 to 143) |
1/0.2 |
6.9 (0.2–38.3) |
67.7 (−9.5 to 430) |
0/0.1 | – | – |
| Non-pelvic central | 4/0.6 |
7.3 (2.0–18.6) |
51.4 (8.1–144) |
1/0.3 |
3.4 (0.1–19.1) |
35.9 (−13.5 to 268) |
3/0.3 |
11.6 (2.4–34.0) |
57.9 (7.6–180) |
| Follow-up, years | |||||||||
| 0–5 | 3/1.2 |
2.6 (0.5–7.6) |
8.7 (−2.5 to 35.8) |
2/1.0 |
2.0 (0.2–7.1) |
6.8 (−5.3 to 42.9) |
1/0.1 |
7.3 (0.2–40.7) |
12.7 (−1.6 to 80.3) |
| 5–30 | 9/3.7 |
2.5 (1.1–4.7) |
12.6 (1.1–31.7) |
7/3.0 |
2.3 (0.9–4.8) |
13.1 (−0.7 to 37.4) |
2/0.7 |
3.1 (0.4–11.0) |
11.4 (−3.5 to 55.7) |
| >30 | 6/2.3 |
2.6 (1.0–5.7) |
45.5 (−1.0 to 132) |
3/1.8 |
1.7 (0.3–4.9) |
19.5 (−19.1 to 113) |
3/0.5 |
6.1 (1.3–17.9) |
127 (6.6–419) |
SIR standardised incidence ratio, AER absolute excess risk (mean excess subsequent primary neoplasms per 10,000 person-years), CI confidence interval.